OTC/supplement combos
This article was originally published in The Tan Sheet
Executive Summary
DSHEA does not prohibit marketing OTC/dietary supplement combinations, CHPA says in a Nov. 29 letter to FDA. "If Congress had intended to outlaw combinations of dietary supplements and OTC drugs, it could have done so," CHPA says. Association also notes precedents allow cosmetic/drugs to make both cosmetic and drug claims, and that an April agreement between CFSAN and CDER "effectively recognized the existence of combination products." Letter follows B.F. Ascher and Omni Nutraceuticals' responses to FDA warning letters concerning their Melagesic PM and Inholtra products, respectively (1"The Tan Sheet" Nov. 12, p. 8)...
You may also be interested in...
Supplement/OTC Combos Have Precedents In Other Categories, Firms State
Prior sale of combination products such as drug/ devices or drug/biologics set a precedent for selling dietary supplement/OTC combination products, B.F. Ascher and Omni Nutraceuticals maintain in separate letters sent to FDA Nov. 6
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.